# Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.

> **NCT07739654** · PHASE3 · RECRUITING · sponsor: **King Edward Medical University** · enrollment: 74 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Cisplatin (modified schedule)
- **DRUG:** Cisplatin
- **DRUG:** Dexametasone
- **DRUG:** Cytarabine (Ara-C)
- **DRUG:** Cytarabine (Ara-C) (Modified schedule)

## Key facts

- **NCT ID:** NCT07739654
- **Lead sponsor:** King Edward Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-10-20
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739654, "Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*